UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2020
Commission file number:001-38775
ITAMAR MEDICAL LTD.
(Name of registrant)
9 Halamish Street, Caesarea 3088900, Israel
(Address of principal executive office)
_____________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FxForm 40-F¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):¨
____________________
CONTENTS
Itamar Medical Ltd. (the"Company" or the"Registrant") hereby announces the results of its Special General Meeting of Shareholders (the"Meeting") held on March 18, 2020.
The Company's shareholders voted upon the proposals on the Meeting's agenda, each of which is described in more detail in the Company's proxy statement for the Meeting, which was attached as Exhibit 99.1 to a Report of Foreign Private Issuer on Form 6-K, submitted to the Securities and Exchange Commission, on February 11, 2020 (the"Proxy Statement").
Only shareholders of record at the close of business on February 17, 2020 were entitled to vote at the Meeting. Each of the proposals on the Meeting's agenda were voted upon and approved by the required majority of the Company’s shareholders.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | ITAMAR MEDICAL LTD. | |
| | By: | /s/ Shy Basson | |
| | | Shy Basson | |
| | | Chief Financial Officer | |
| | | |
| Date: March 19, 2020 | | |
